Abstract
Arthritics diseases, such as rheumatoid arthritis and osteoarthritis are chronic inflammatory and one of the most prevalent health conditions that cause disability (pain and functional limitation of joints). Despite the research advances, the treatment of those pathological conditions remains ineffective, since the pharmacological therapy is palliative, reducing only the symptoms and, in some cases, the chronic progression of the disease. In this context, the development of new formulations for controlled release would be interesting for reducing the number of injections and would also increase the patient compliance. In this article, we present a review of the cyclodextrin (CD)-based delivery systems focusing from conventional guest-host inclusion complexes and CD-polysulphates, until supramolecular architectures such as drug-CD-polymers conjugates, pseudorotaxanes, hydrogels as well as double-carrier systems and other systems. In particular, this article focuses the main CD-based delivery systems described in the literature emphasizing their possible administration by intra-articular route on the treatment of arthritic diseases, concentrating on their development and also performance as in vivo experimental therapeutic systems.
Keywords: Arthritic diseases, cyclodextrins, drug-conjugate polymers, drug-delivery systems, inclusion complex, osteoarthritis, pseudorotaxanes, rheumathoid arthritis.
Current Pharmaceutical Design
Title:Cyclodextrin-Based Delivery Systems for Arthritic Diseases: From Development to Experimental Therapeutics
Volume: 21 Issue: 33
Author(s): Monica Helena Monteiro Nascimento, Alessandra Cristina Santos Akkari, Kelly Cristina Freitas Mariano, Antonio Sergio Kimus Braz, Christiane Bertachini Lombello and Daniele Ribeiro de Araujo
Affiliation:
Keywords: Arthritic diseases, cyclodextrins, drug-conjugate polymers, drug-delivery systems, inclusion complex, osteoarthritis, pseudorotaxanes, rheumathoid arthritis.
Abstract: Arthritics diseases, such as rheumatoid arthritis and osteoarthritis are chronic inflammatory and one of the most prevalent health conditions that cause disability (pain and functional limitation of joints). Despite the research advances, the treatment of those pathological conditions remains ineffective, since the pharmacological therapy is palliative, reducing only the symptoms and, in some cases, the chronic progression of the disease. In this context, the development of new formulations for controlled release would be interesting for reducing the number of injections and would also increase the patient compliance. In this article, we present a review of the cyclodextrin (CD)-based delivery systems focusing from conventional guest-host inclusion complexes and CD-polysulphates, until supramolecular architectures such as drug-CD-polymers conjugates, pseudorotaxanes, hydrogels as well as double-carrier systems and other systems. In particular, this article focuses the main CD-based delivery systems described in the literature emphasizing their possible administration by intra-articular route on the treatment of arthritic diseases, concentrating on their development and also performance as in vivo experimental therapeutic systems.
Export Options
About this article
Cite this article as:
Monteiro Nascimento Helena Monica, Santos Akkari Cristina Alessandra, Freitas Mariano Cristina Kelly, Kimus Braz Sergio Antonio, Lombello Bertachini Christiane and de Araujo Ribeiro Daniele, Cyclodextrin-Based Delivery Systems for Arthritic Diseases: From Development to Experimental Therapeutics, Current Pharmaceutical Design 2015; 21 (33) . https://dx.doi.org/10.2174/1381612821666150820104427
DOI https://dx.doi.org/10.2174/1381612821666150820104427 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacophore Identification for Sigma-1 (σ1) Receptor Binding: Application of the "Deconstruction - Reconstruction - Elaboration" Approach
Mini-Reviews in Medicinal Chemistry Current and Future Therapeutic Strategies to Target Inflammation in Stroke
Current Drug Targets - Inflammation & Allergy Immunotherapy Approaches in Cancer Treatment
Current Pharmaceutical Biotechnology Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies
Current Drug Metabolism Meet Our Editorial Board Member
Current Medicinal Chemistry Lifestyle Choices and Endothelial Function: Risk and Relevance
Current Vascular Pharmacology Targeting Cytokines: Production and Characterization of Anti-TNF-α scFvs by Phage Display Technology
Current Pharmaceutical Design Interleukin-6 Trans-Signaling and Colonic Cancer Associated with Inflammatory Bowel Disease
Current Pharmaceutical Design The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application Prospects
Current Medicinal Chemistry Introduction from Editor-in-Chief
Current Rheumatology Reviews General Molecular Biology and Architecture of Nuclear Receptors
Current Topics in Medicinal Chemistry Designing Proteins That Work Using Recombinant Technologies
Current Pharmaceutical Biotechnology Potential Applications of FDG-PET/CT in COPD: A Review of the Literature
Current Molecular Imaging (Discontinued) The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets The Prevention of Preterm Labour - Corticotropin Releasing Hormone Type 1 Receptors as a Target for Drug Design and Development
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member:
Current Traditional Medicine Tablet Formulation of a Synthesized Celecoxib Potassium Salt and Development of a Validated Method for Its Analysis
Current Pharmaceutical Design 4-Mer Hyaluronan Oligosaccharides Stimulate Inflammation Response in Synovial Fibroblasts in Part via TAK-1 and in Part via p38-MAPK
Current Medicinal Chemistry Biologicals Dramatic Advances in the Treatment of Psoriasis
Current Pharmaceutical Design